Medicenna Therapeutics Corp MDNAF

$MDNAF we will see only intestinal data from mdna11 at sitc ?

$MDNAF oncology doesn’t always follow common sense bcos biology in living tissue is not always linear. If a drug works at 60 µg, you’d assume it works even better at 90 µg —This is the story of MDNA11. All known MDNA11 responses all came at 60 µg, below the RP2D of 90 µg. In other field, that would be a breakthrough. In pharma, it’s dismissed as a fluke until you repeat it at your selected RP2D. Regulators and BD teams don’t accept dose escalation signals those who did with Synthrox &Nektar can tell the story. Everything ultimately lives or dies at the dose you choose as RP2D.heading into SITC with a level of clarity per the title is a relief

$MDNAF I blame Canadians for the sell-off right at the close! lol

$MDNAF A clinical program generally needs 3 layers of validation before it can credibly “break out”: (1) Biological / Mechanistic Validation (2) Safety & Tolerability Validation (3) Clinical Efficacy Validation — the true breakout trigger The 1st 2 almost never move a stock in a durable way. You get a spike, then a sell off, we've seen this 3x with MDNA because mechanism and safety alone are not enough to bring in the big players —who anchor a valuation. They wait for the only thing that matters MDNA11 already checks the 1st 2 boxes. But lacks the most important validation: clinical proof of efficacy. That’s why the approved SITC title — explicitly emphasizing clinical efficacy — is so telling. It signals that Mdna's finally ready to address the 1 missing pillar. If SITC delivers confirmed, durable tumor shrinkage at therapeutic dose, MDNA11 transitions from “scientifically interesting” to “clinically undeniable.” That's the moment the MDNA becomes investable for serious capital & pharma

$MDNAF hype was only back for 1 day 😂

$MDNAF So which one of the four of us bought today … ?? Surely no one else is watching?

$MDNAF how much time since we had more than 400k volume ? 😂😂😂

$MDNAF Let’s go